Psilocybin research and implementation study for mental health and substance use (PRISM) - the rapid shift in public perception of psychedelics, coupled with the expansion of their use and policy…
Active Grant Awarded
- Award ID
- R01DA060253
- Recipient
-
Oregon Health & Science University UEI NPSNT86JKN51
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $736,713
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date 17% complete
- Place of performance
- Portland, OR 97239, USA
Award details come from USAspending.gov.
About this award
The National Institute on Drug Abuse, within the Department of Health and Human Services National Institutes of Health, awarded Oregon Health & Science University $736,713 on February 3, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) for Grant R01DA060253, the Psilocybin Research and Implementation Study for Mental Health and Substance Use (PRISM). The program supports implementation research on the prevention, diagnosis, and treatment of drug use, misuse, and addiction.
PRISM enrolls a cohort of people who use substances and receive Oregon's state-regulated psilocybin services and compares them with a group who would access those services if available. Over 12 months, the study uses longitudinal surveys and qualitative interviews to detect safety risks and benefits, identify substances and subpopulations responsive to psilocybin's effects, and elicit stakeholder views on long-term safety and changes in substance use. Ultimate completion is November 30, 2030. Place of performance is Portland, Oregon 97239.
Legacy Emanuel Hospital & Health Center, a Portland-based nonprofit hospital, holds a PRISM sub-award dated April 8, 2026, issued by the recipient.
Description
Psilocybin research and implementation study for mental health and substance use (PRISM) - the rapid shift in public perception of psychedelics, coupled with the expansion of their use and policy reform across the united states, has created a unique opportunity to assess the real- world impacts of psychedelic use. Over 7,000 people in oregon have received legal, supervised psilocybin experiences. Similar services are set to begin in colorado in 2025, and nine other states are currently considering psychedelic services legislation. Although early phase trials suggest psilocybin may be safe and effective for treating some mental health and substance use disorders (e.g., tobacco use), IT is not known whether these effects extend to community- based settings with less standardized screening and counseling support. There is an urgent need to assess the safety of these programs and their impact on substance use, before more voters and policymakers are asked to consider their merits and drawbacks. The psilocybin research and implementation study for substance use and mental health (PRISM) study is designed to fill this GAP by enrolling a cohort of individuals who use substances and receive oregon's state-regulated psilocybin services and comparing them to a group of people who would access these services, if they were available. Using 12 months of rigorous longitudinal surveys and qualitative interviews, PRISM will detect potential safety risks and benefits of regulated psilocybin services and identify specific substances and subpopulations that may be responsive to psilocybin's effects. The study has three aims: 1) assess the impact of state- regulated psilocybin services on safety events in people who use substances, 2) assess the impact of state-regulated psilocybin services on substance use, and 3) elicit stakeholder views of the impact of state-regulated psilocybin services on long-term safety and changes in substance use. The PRISM study seeks to generate rigorous real-world evidence that can effectively guide state and federal decision-making. The timing of this work is critical, given the rapid expansion of psychedelic policy reform across the united states. The findings will help shape policies that maximize potential benefits of psilocybin services while minimizing risks, offering a scientifically grounded framework for public health strategies, harm reduction efforts, and future psychedelic regulations.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Legacy Emanuel Hospital & Health Center | $88,416 |
Quick answers
Who received award R01DA060253?
R01DA060253 was awarded to Oregon Health & Science University by National Institute on Drug Abuse (National Institutes of Health) on February 3, 2026.
How much is award R01DA060253 worth?
$736,713 has been obligated on R01DA060253.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award